Harpreet Singh on Clinical Trial Eligibility in the Elderly Cancer Population
Harpreet Singh of the FDA discusses how clinical trial populations are not always reflective of the population of patients who eventually end up getting treated by the therapies.
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC